Aiforia lands new partner in South Korea

Translation: Original published in Finnish on 10/8/2024 at 11:15 am EEST.

We see clear value in international partnerships for building Aiforia's business. Having a presence in multiple markets is important for both competitive tenders and implementing software deployments, but it is also expensive and, in our view, often inefficient to do alone. We see the announced partnership with Urban Datalab as complementary to Aiforia's ability to sell and deliver its solutions in South Korea. In practice, the potential benefits of the partnership will only be realized through the success of clinical customer benefits and their implementation. Our forecasts assume widespread success in commercializing Aiforia's technology, so the release does not affect our forecasts or our view of the company.

The company also receives a small amount of public funding and visibility through its participation in an EU project

Aiforia also announced on Monday that it joined the five-year Thera4Care project launched in October. The EU-funded Innovative Health Initiative joint undertaking (IHI-JU) consists of 29 partners from top European academic and clinical institutions, SMEs and patient organizations. Aiforia, the only company in the consortium focusing on digital pathology AI solutions, has been granted 300,000 euros in funding to support the development of robust AI solutions for clinical decision support and predictive modeling to enable personalized medicine. In our view, Aiforia's entry into the project will at least bring good visibility among industry players and a small amount of funding, although we estimate its impact on the company's commercialization to be limited.